Structured evidence table for Coq10 Blood Pressure Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Coq10 Blood Pressure Randomized Trial | Background/objectives Oxidized low-density lipoprotein (oxLDL) has emerged as a promising biomarker of oxidative burden and cardiovascular risk. | 2 | Leaovitavat R (2026) | Effects of Ubiquinol on Oxidized Low-Density Lipoprotein in Prediabetic Patients: A Randomized, Double-Blinded, Placebo-Controlled Study. |
| Coq10 Blood Pressure Randomized Trial | Conclusions Daily ubiquinol (100 mg/day) for 12 weeks was associated with a significant within-group decrease in plasma oxLDL among prediabetic participants; however, the between-group difference versus placebo was not significant. | 2 | Leaovitavat R (2026) | Effects of Ubiquinol on Oxidized Low-Density Lipoprotein in Prediabetic Patients: A Randomized, Double-Blinded, Placebo-Controlled Study. |
| Coq10 Blood Pressure Randomized Trial | This study is aimed at evaluating the effect of ubiquinol supplementation, a potent lipophilic antioxidant, on oxLDL levels in prediabetic patients. | 2 | Leaovitavat R (2026) | Effects of Ubiquinol on Oxidized Low-Density Lipoprotein in Prediabetic Patients: A Randomized, Double-Blinded, Placebo-Controlled Study. |
| Coq10 Blood Pressure Randomized Trial | 3 Elevated intraocular pressure (IOP) remains the only proven modifiable risk factor and the principal target of all current pharmacological and surgical interventions. | 3 | Hanyuda Akiko (2026) | Oxidative Stress in Glaucoma: From Pathogenic Mechanisms to Emerging Antioxidant Therapies |
| Coq10 Blood Pressure Randomized Trial | Evidence from human ocular samples and animal models consistently demonstrates ROS accumulation and oxidative biomarker elevation across all anatomical compartments relevant to glaucoma: the trabecular meshwork (TM), the optic nerve head (ONH), and the RGC layer [,]. | 3 | Hanyuda Akiko (2026) | Oxidative Stress in Glaucoma: From Pathogenic Mechanisms to Emerging Antioxidant Therapies |
| Coq10 Blood Pressure Randomized Trial | In the anterior segment, oxidative stress may impair ocular biomechanical integrity, including corneal hysteresis, due to oxidative collagen cross-linking, leading to increased vulnerability to IOP fluctuation [,]. | 3 | Hanyuda Akiko (2026) | Oxidative Stress in Glaucoma: From Pathogenic Mechanisms to Emerging Antioxidant Therapies |
| Coq10 Blood Pressure Randomized Trial | 1 2 Glaucoma constitutes a heterogeneous group of progressive optic neuropathies and represents the leading cause of irreversible blindness globally. | 3 | Hanyuda Akiko (2026) | Oxidative Stress in Glaucoma: From Pathogenic Mechanisms to Emerging Antioxidant Therapies |
Source documents